Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Brain tumor endpoints

Executive Summary

Clinical trial endpoints for primary brain tumors will be the topic of the next public workshop in FDA's series of oncology endpoint meetings, to be held Jan. 20. "Issues identified in the workshop will be further discussed before the Oncologic Drugs Advisory Committee and thereafter will be detailed in FDA guidance documents," the agency said Nov. 22. The agency has previously hosted public meetings on lung, colorectal and prostate cancers (1"The Pink Sheet" June 28, 2004, p. 40). The workshop will be held at the Marriott in North Bethesda, Md., beginning at 8 a.m....

You may also be interested in...



Prostate Cancer Trial Composite PSA/Bone Scan Endpoint Suggested By FDA

FDA could consider an endpoint for prostate cancer trials that combines PSA kinetics and bone scan results, FDA Office of Cellular, Tissue & Gene Therapies Oncology Group Leader Steven Hirschfeld, MD/PhD, suggested

European CHMP Opinions and MAA Updates

This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the European Union, and updates on EU marketing authorization changes recommended by the CHMP.

UK’s NICE Backs Two Microsphere Products For Liver Cancer But Says No To Another

Health technology assessment body NICE has now recommended that selective internal radiation therapy can be used on England’s National Health Service for treating advanced liver cancer.

Topics

UsernamePublicRestriction

Register

LL005491

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel